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PURPOSE. Photoaversion (PA) is a disabling and ubiquitous feature of achromatopsia (ACHM).
We aimed to help define the characteristics of this important symptom, and present the first
published assessment of its impact on patients’ lives, as well as quantitative and qualitative PA
assessments.
METHODS. Molecularly confirmed ACHM subjects were assessed for PA using four tasks:
structured survey of patient experience, novel quantitative subjective measurement of PA,
visual acuities in differing ambient lighting, and objective palpebral aperture-related PA
testing.
RESULTS. Photoaversion in ACHM was found to be the most significant symptom for a
substantial proportion (38%) of patients. A novel subjective PA measurement technique was
developed and demonstrated fidelity with more invasive paradigms without exposing often
very photosensitive patients to brighter light intensities used elsewhere. An objective PA
measurement was also refined for use in trials, indicating that higher light intensities than
previously published are likely to be needed. Monocular testing, as required for trials, was also
validated for the first time.
CONCLUSIONS. This study offers new insights into PA in ACHM. It provides the first structured
evidence of the great significance of this symptom to patients, suggesting that PA should be
considered as an additional outcome measure in therapeutic trials. It also offers new insights
into the characteristics of PA in ACHM, and describes both subjective and objective measures
of PA that could be employed in clinical trials.
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Achromatopsia (ACHM) is an autosomal recessive conditionaffecting 1 in 30,000 people1 associated with a lack of cone
photoreceptor function.2 It is characterized by presentation at
birth/early infancy with pendular nystagmus, poor visual acuity
(VA; approximately logMAR 1.0), a lack of color vision, and
marked photophobia/hemeralopia. To date, six genes have
been associated with ACHM (CNGA3,3 CNGB3,4 GNAT2,5
PDE6C,6 PDE6H,7 and ATF68), with all except the lattermost
encoding components of the cone-specific phototransduction
cascade. Disease-causing variants in CNGA3 and CNGB3
account for about 80% of cases.9–12
Several studies have demonstrated effectiveness of gene-
based therapy to restore cone function in animal models of
ACHM,13–16 resulting in the commencement of phase I/II
human gene replacement trials (ClinicalTrials.gov identifiers:
NCT02599922, NCT03001310, NCT02610582, NCT02935517).
A phase I/II study using ciliary neurotrophic factor (CNTF) in
CNGB3-associated ACHM17 showed no improvement in phot-
opic ERG responses, VA, or color discrimination, but reported
reduced sensitivity to bright lights in treated eyes.
Discomfort and/or avoidance of bright lights is a classical
feature of ACHM.1 The terminology to describe this phenom-
enon is varied, and its usage can be inconsistent. Photoaversion
(PA) is the avoidance of light due to discomfort and or/impaired
VA, whereas photophobia and photo-oculodynia are the
sensation of pain from a normally non-noxious light source.
Hemeralopia refers to reduced VA in photopic ambient viewing
conditions. Despite the ubiquitous nature of this symptom in
ACHM, there is limited associated literature.
A reduction in achromat VA with increasing luminance has
been documented previously,18 and a few case reports have
suggested that photophobia may be one of the more
debilitating symptoms.19–21 Recently, Zelinger et al.22 described
measurements of PA made in three CNGA3 ACHM patients.
They assessed PA by measuring the percentage change in
palpebral aperture under different lighting conditions. They
reported that, when lighting conditions changed abruptly from
complete darkness to dim light, normal subjects’ palpebral
apertures did not differ, but that the three CNGA3 patients
tested showed an approximately 50% reduction. However,
there remains to date no evidence base in the literature as to
which of the aspects of PA (e.g., discomfort or reduced vision)
is most bothersome to ACHM patients, nor has there been any
structured assessment of patient-reported experiences of PA
and its effect on their daily living. Given the potential
therapeutic effect on this symptom by human interventional
trials, this study attempts to provide some further data on this
topic.
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Patients in the aforementioned CNGB3 human CNTF
treatment trial17 reported that treated eyes were less sensitive
to light than their untreated eyes; this diminished photophobia
was postulated to be due to reduced rod sensitivity, given that
CNTF downregulates rod phototransduction. If reduced
photophobia is going to be one of the benefits of intervention,
then more objective measures of this albeit subjective
symptom will be needed moving forward. Moreover, the
importance of assessing what a patient experiences and might
want from future treatments is increasingly recognized in
global healthcare structures, such as the UK’s National Health
Service (NHS).
The proposed mechanisms of photophobia are multiple and
not fully understood.23 The relative effect of various properties
of light has been investigated in other patient groups who
suffer from PA, but not in ACHM. Migraineurs have been found
to have lower discomfort thresholds than controls for shorter
wavelength (SW, blue) and long wavelength (LW, red) light
compared to middle wavelength (green) light.24 Stringham et
al.25 showed that normal subjects’ increasing PA (as measured
by electromyography [EMG] of the squinting response)
correlated with decreasing stimulus wavelength, which they
postulated acts as a mechanism biased to protect against SW
light.
The greater sensitivity to SW light may relate to the
discovery of a new class of photoreceptor: melanopsin-
containing intrinsically photosensitive retinal ganglion cells
(ipRGCs), which detect nonimage forming light and constitute
1% to 3% of the GC population.23,26,27 Intrinsically photosen-
sitive RGCs have been implicated as mediators of behavioral
functions including circadian rhythm regulation, mood and
migraine-associated photophobia,28 and are more sensitive to
SW light.29 Given that both rod and cone input modulates
ipRGC output,28 the absence of functional cones in ACHM
might be expected to affect output from ipRGCs, either directly,
or via a bystander effect on rods due to absence of cones.
The effect of stimulus location has also been examined in
normals, demonstrating an increase in PA thresholds (as
measured by EMG) with retinal eccentricity30; these authors
propose that PA in normals is thus biased to prevent the central
retina from exposure to intense light.
Notwithstanding these studies, there is a general paucity of
data in the literature regarding measurement of PA. This may
relate to the inherent difficulty in measuring such a subjective
phenomenon as discomfort or pain. A PubMed search (March
25, 2017) for any of the terms in the title (‘‘photoaversion,’’
‘‘photophobia,’’ ‘‘photo-oculodynia,’’ or ‘‘hemeralopia’’) re-
turned a total of only just over 100 articles in the last decade;
the majority from the migraine literature, with only about 20
including retinal causes.
Previously described measurements of bright light intoler-
ance or photophobia in conditions such as migraine or
blepharospasm, where light intensities are increased until
evident discomfort is induced, are likely to be unsuitable in
ACHM, given these patients often experience exquisite
photophobia. For example, methods previously used have
increased light intensity up to 23,500 lux31—which is
approximately equivalent to the upper range of full day-
light—until a frank sensation of discomfort was reached.
Aguilar et al.32 used a paradigm of self-reporting of photopho-
bia thresholds with increasing light intensity from a light-
emitting diode array in their comparison of 7 ACHM subjects
with 11 normals, and found that the 2 groups had significantly
different photosensitivity thresholds (0.75 6 0.66 log[lux] and
3.32 6 0.66 log[lux], respectively; P < 0.001).
A testing paradigm for PA in ACHM is therefore required
that uses sufficiently dim lighting to not cause undue
discomfort to patients, especially given they may need to
undergo these tests on a repeated basis in the setting of a
therapeutic trial.
METHODS
The assessment of PA in ACHM was subdivided into four tasks:
(1) a structured patient survey (to obtain subjective patient
information about the effect of this inherently subjective
phenomenon on patients’ lives); (2) a quantitative subjective
measurement of PA (in order to try and quantify the subjective
experience of PA using a standardized method); (3) a
functional measure of VA in different ambient light settings;
and (4) an objective measure of palpebral aperture narrowing
with PA, as adapted and developed from Zelinger et al.22 for
use in therapeutic trials.
The task protocols adhered to the Tenets of the Declaration
of Helsinki, and were approved by the Moorfields Eye Hospital
Ethics Committee. Informed consent was obtained from all
subjects before entering the study. All patients tested had a
molecularly proven diagnosis of ACHM.
Structured Patient Survey
A structured survey (Supplementary Material) was devised in
order to obtain subjective information about how PA affects the
lives of ACHM patients and their activities of daily living
(ADLs). To the best of our knowledge, there has been no
structured assessment of the effect of PA in ACHM from the
patient’s point of view reported in the literature previously
(PubMed search March 25, 2017; title keywords: ‘‘achroma-
topsia,’’ ‘‘rod monochromatism,’’ ‘‘photoaversion,’’ ‘‘photo-
phobia’’). The survey consisted of 13 questions, in a
combination of multiple choice; open (free text); and closed
structured questions. This survey was developed and adapted
specifically for ACHM from a previously published survey
designed for photophobia in benign essential blepharospasm.31
Quantitative Subjective Measurement of PA Task
Thresholds of EMG-derived photophobia have been shown to
have a high correlation with subjects’ ratings of threshold
photophobia.25 Given this correlation, a 0 to 100 psychometric
scale rating was employed so that subjects could rate the
subjective sensation of viewing presented stimuli on a relative
comfort scale, where 0 was no PA at all and 100 was a
sensation of PA that the subject felt they could not tolerate and
would want to look away from the display screen. Finer
scaling, such as that employed here, has been shown to
substantially enhance the ability to detect smaller degrees of
subjective change.33
Patients were advised that no stimuli would be expected to
cause pain, and that all stimuli were presented on a standard,
commercially available PC monitor. This was important
because the majority of ACHM patients who were asked to
take part explicitly asked not to be exposed to any ‘‘bright
lights’’ due to their PA. Different stimuli were used in order to
explore the potential PA-inducing attributes of various qualities
of the stimulus, such as intensity, size, location, and color. We
tested 26 normals and 26 ACHM subjects.
A commercial spectrophotometer (Konica Minolta Chroma
Meter CS100A; Konica Minolta, Osaka, Japan) was used to
measure the luminance of the stimuli as presented on a
dedicated 58.4-cm monitor display (S2340L; Dell, Inc., Round
Rock, TX, USA) generated using a slideshow program (Power-
Point; Microsoft Corp., Redmond, WA, USA) on a laptop PC
(Inspiron 5000 series; Dell, Inc.) via a high-definition multime-
dia interface cable. The monitor had the following settings that
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were maintained at all times: resolution, 19203 1080 at 60Hz;
preset mode, standard; brightness, 100; contrast, 100; color
settings, RGB display; sharpness, 50.
Stimuli for Quantitative Subjective Measurement of PA
Task. In order to maintain the isoluminance of the colored
stimuli to that of the dimmer (gray) stimuli, measurements of
the luminance of the monitor display were taken at various
RGB values for each of the red, green, blue, and gray/white
stimuli and plotted in Figure 1.
The maximum nonwhite stimulus luminance of 21 cd/m2
was limited by the maximal luminance of the blue stimulus
(see the dotted line in Fig. 1), and the approximate R (red
stimulus); G (green stimulus); and RGB (gray stimulus) values
were then interpolated from this graph. Spectrophotometer
measurements on the stimuli were then made in experimental
conditions to fine-tune the interpolated RGB values to all, given
a measured luminance of 21 cd/m2 for all nonwhite stimuli.
The RGB values required to do this were as follows: red
stimulus, R¼155, G¼0, B¼0; blue stimulus, R¼0, G¼73, B¼
0; green stimulus, R¼ 0, G¼ 0, B¼ 255; gray stimulus, R¼ 71,
G¼ 71, B¼ 71. These RGB settings displayed stimuli with x, y
chromaticity coordinates as measured by the spectrophotom-
eter as follows: white/gray, x¼0.331, y¼0.349; red, x¼0.616,
y¼ 0.338; green, x¼ 0.316, y¼ 0.559; and blue x¼ 0.161, y¼
0.081. A spectroradiometer (Radoma GS-1240; Gamma Scien-
tific, San Diego, CA, USA) was used to measure the peak
wavelength of the colored stimuli, and gave measured peak
wavelength values of red, green, and blue as 615, 538, and 447
nm, respectively.
The room in which the experiment was undertaken was
illuminated by an incandescent 40-W corner stand-lamp,
creating a subdued ambient illumination, in order to prevent
dark adaptation. All illuminance/luminance measures were
taken at the plane of the patient’s eyes. The monitor was left
on, displaying the large bright white circle calibration stimulus
for 20 minutes before any measurements or testing. The
monitor displayed bright white stimuli of 250 cd/m2 lumi-
nance, and dimmer gray or colored (red, green, or blue) stimuli
of 21 cd/m2 luminance. The brighter stimuli luminance
equaled the luminance of the ETDRS lightbox charts with
ambient room lighting on, at which many ACHM patients had
previously reported PA anecdotally during routine VA mea-
surements. The black background screen on the monitor
(luminance 1 cd/m2) had an illuminance of 4.2 lux in the
ambient lighting. Figure 2 shows the 20 stimuli that were
randomly presented during each of the three trial runs.
FIGURE 1. Spectrophotometry RGB monitor initial stimuli calibration. Interpolation of the luminance recordings taken for each of the red, green,
blue and gray/white monitor stimuli at various RGB values (max 255). This plot allowed the setting of the RGB values in order to maintain
isoluminance across all colors (limited by blue at 255).
FIGURE 2. The 20 stimuli used to assess PA attributes in ACHM. All
gray, red, green, and blue stimuli were designed to be isoluminescent
(21 cd/m2), while the white stimuli had a higher luminance (250 cd/
m2). From the top left are: the five large central circle stimuli (white,
dim [gray], red, green, and blue); the five small central circle stimuli
(vide supra); the five large peripheral annulus stimuli (vide supra); and
the five small peripheral annulus stimuli (vide supra). All large stimuli
(central circle or peripheral annulus) were designed to have an area
four times that of the smaller stimuli (central circle or peripheral
annulus).
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The illuminance of the large bright stimuli was 36.0 lux for
both the peripheral and central stimuli, and for the large dim or
colored stimuli was 7.0 lux for both the peripheral and central
stimuli. These values for the small stimuli were 13.2 lux
(bright) and 5.4 lux (dim or colored), respectively.
The large circle stimulus subtended a visual angle of 25.48,
and the small circle 12.78. All of the peripheral (annulus)
stimuli also had an inner diameter of 12.78, with the outer
diameters subtending 28.28 (large annulus) and 18.18 (small
annulus). All large stimuli (central circle or peripheral annulus)
had an area four times that of the smaller stimuli (central circle
or peripheral annulus).
Before testing of any subject, and after the display monitor
had been left on for 20 minutes, a luminance reading was taken
of a standard calibration screen (the large white circle
stimulus) to verify that the luminance was 250 cd/m2, and of
each of the dim, red, green, and blue stimuli to also verify that
their luminance was 21 cd/m2 as expected. The patient’s head
rested in a chin-rest supported on a height-adjustable table,
maintaining the patient’s eyes 40 cm from the monitor display
screen.
Testing Strategy for Quantitative Subjective Measure-
ment of PA Task. The patient was asked to look at a fixation
target in the center of the screen at all times and the test was
carried out binocularly. The patient was then presented with
the background screen with fixation target and advised that
three stimuli would now be presented (large white stimulus,
followed by small gray stimulus, followed by small white
stimulus) in order for the patient to familiarize themselves with
the testing paradigm and the approximate range of stimulus
brightness. The patient could rate these stimuli, although these
ratings were not recorded. All stimuli throughout the
experiment were presented for 2 seconds, with 5-second
intervals between stimuli. The background screen then
returned and the patient was instructed that recorded testing
would begin. The 20 stimuli were subsequently presented in
random order, each with a duration of 2 seconds before
reverting to the black background screen, at which point the
patient was asked to rate the stimulus on a subjective PA scale
from 0 to 100, this score being recorded. Each patient
completed three runs through the stimuli in succession, with
a short break between runs.
Visual Acuity Measurements in Different Ambient
Lighting Conditions
The best-corrected logMAR visual acuity (BCVA) of 26 ACHM
patients was measured (in each eye and binocularly) in two
ambient lighting conditions to assess the effect this had on
recorded logMAR scores. We measured BCVA: (1) with
standardized overhead fluorescent lighting on and the VA
chart lightbox on. Precision Vision lightboxes (Precision
Vision, Woodstock, IL, USA) were used, and were illuminated
with two cool daylight 20-W fluorescent tubes (illuminance at
patient viewing position of 400 lux and luminance 250 cd/m2);
and (2) with overhead lighting off and the VA chart lightbox on
(illuminance at patient viewing position of 7 lux and
luminance 155 cd/m2).
Palpebral Aperture Measurements
The onset of palpebral aperture narrowing has been shown to
correspond to the first reports of photophobic discomfort with
increasing lighting conditions in normal subjects.34 Given the
striking finding of Zelinger et al.22 in their binocular analysis of
an approximately 50% reduction in palpebral aperture in
achromats, we sought to explore this experimental paradigm
in a larger number of patients to ascertain if these findings
could be replicated and used as a further measure of PA in
ACHM patients participating in clinical trials.
Palpebral Aperture Measurements – Methods. As per
Zelinger et al.,22 subjects were dark-adapted for 10 minutes
while resting their head on a chin-rest in a custom-built
Ganzfeld stimulator in complete darkness. After this period,
standard video capture software was activated for a 10-second
period, with input from an infrared camera located in the
stimulator that recorded a video image of the subject’s eye in
the dark. After 5 seconds of video capture in the dark, the
background light of the stimulator (which had been calibrated
using a spectrophotometer to 0.6 cd m2) was activated and a
further 5 seconds of video captured in the light ambient
conditions. The vertical palpebral aperture height through the
pupillary center in the dark and light ambient conditions was
then measured using manual co-ordinate analysis of the eyelid
positions on the captured video, using open source software to
post-process the video segments (kinovea.org).
The vertical palpebral aperture in the dark was defined as
100%, and the corresponding percentage change in palpebral
aperture with the onset of the light was then calculated using
the co-ordinate analysis of the eyelid positions on the video
image. A preliminary review of the first three achromat
subjects tested suggested that the palpebral aperture narrow-
ing we observed would not be nearly as substantial as the 50%
reported by Zelinger et al.22 when using 0.6 cd m2, and so an
additional brighter light condition was introduced, following
the same procedure as described above, also with a separate 10
minutes of dark adaptation preceding the palpebral aperture
measurements and light onset. In the first instance, 70 cd/m2
was tried, but the initial ACHM patients tested closed their eyes
completely to this intensity and verbally reported that it caused
them marked discomfort. A lower intensity of 16.6 cd/m2 was
subsequently tried, which was reported as bright but tolerable
by the initial achromats tested.
Given that the initial treatment trials for ACHM have and are
likely to administer therapy to one eye only, the relative effect
of binocular versus uniocular PA would need to be borne in
mind in a trial measure of PA. Given that binocular viewing, as
assessed by Zelinger et al.22, had been shown to be associated
with a relatively lower photophobia threshold in migraineurs
compared to uniocular viewing,35 we also undertook monoc-
ular assessments of PA in our ACHM subjects, using the same
conditions as described above, to ascertain if there was any
difference between monocular and binocular viewing condi-
tions.
RESULTS
Demographics
A total of 26 molecularly proven ACHM patients completed the
structured survey, quantitative subjective measurement of PA
task, and VA measurements in different ambient lighting
conditions task. Of these, 16 were male (62%) and 10 were
female (38%), and their mean age was 32 years (SD, 612.6
years). Of the patients in the study, 16 were CNBG3 (61%); 4
were CNGA3 (15%); 3 were ATF6 (12%); 2 were GNAT2 (8%);
and 1 was PDE6C (4%).
Structured Patient Survey
All of the 26 ACHM patients (100%) surveyed indicated that
light generally causes them discomfort. This was given a
median rating of 70 out of 100 (on a scale of 0–100, with 0
being no discomfort and 100 being unbearable discomfort;
IQR: 60–80). Interestingly, only 2 out of 26 (8%) patients said
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that bright lights caused them more issues with discomfort/
pain as opposed to increased difficulty in seeing (24/26; 92%).
A total of 25 patients (96%) stated that they wore visual aids
such as sunglasses to try and reduce PA. Of those that did, 8
(32%) wore them only outdoors; 1 (4%) wore them only
indoors; and 16 (64%) wore them both indoors and outdoors.
Also, 19 of these 25 patients (76%) reported that the need for
such aids made them feel self-conscious or embarrassed in
social situations.
Of those in the study, 23 of the 25 patients (92%) whose
ADLs were affected by light sensitivity stated that this symptom
limited their ability to carry out their ADLs; 18 (72%) said they
had mild to moderate limitation in their ability to carry out
ADLs; and 5 (20%) said they experienced marked limitation.
One common theme among eight patients surveyed (31%) was
that they felt their light sensitivity increased their perceived
risk of accidents, and they stated that they had to take extra
care to mitigate this, writing comments such as ‘‘increased risk
factor of accidents’’ and limitation in ‘‘crossing roads.’’
The breakdown to question 10 (‘Which one aspect of your
vision would you improve?’) is show in Figure 3. A total of 14
(54%) patients said that they would choose improved vision for
reading/visual acuity and only 2 (8%) said to enable color
vision. Of particular interest, a significant proportion (10
patients [38%]) said that they would chose to improve their PA
above all other aspects of their visual impairment.
Survey findings showed that 2 patients (6%) reported that
PA has had no effect on their ability to do any kind of work; 16
(62%) indicated they had a mild to moderate limitation; and 8
(32%) said they had experienced a marked limitation in this
regard. A total of 19 patients (73%) stated that they felt that
their PA has impacted on their employment prospects, with 9
patients (35%) wrote comments about how their career choice
was limited to not involving work outdoors.
Quantitative Subjective Measurement of PA
In this exploratory study, we used descriptive statistics to
ascertain the effects of various stimulus attributes on subjective
PA scores (SPAS). We aimed to answer several exploratory
questions about PA in ACHM compared to normals, such as the
effect of stimulus hue, intensity, location, and size. More
complex models for analyzing the data were considered, but
due to technical limitations preventing a fully factorial design
and a limited sample size, we were not able to achieve suitable
convergence for use of these statistical models.
The results of all testing conditions are shown in Figure 4.
The score for each stimulus for each patient was the mean of
three runs.
Themost salient initial observation is that with either large or
small stimuli, and with either central (circle) or peripheral
(annulus) stimuli, the SPAS were significantly higher for the
brighter (white stimuli (250 cd/m2) as opposed to the dimmer
(gray) or colored stimuli (all of which were isoluminescent at 21
cd/m2) in both the normal and ACHM groups. Comparing the
bright to dim stimuli alone, the mean SPAS scores were sta-
tistically significantly higher (paired t-test) for bright stimuli in
all comparable conditions (i.e., size [large or small] and location
[central circle or peripheral annulus]) in both normal and ACHM
subjects (Table). This is reassuring evidence that this novel SPAS
testing paradigm is broadly valid in terms of detecting greater
subjective discomfort with more intense stimuli.
Given that the same pattern of results was seen across the
four size/location combinations (as represented in the four
graphs in Fig. 4), we further analyzed the data from the large
central (circle) stimuli to examine the effect of color on SPAS
between the four isoluminant stimuli (i.e., gray, red, green, and
blue). We chose the large stimulus as this represented the higher
illuminance (36.0 lux), and so would be expected to have the
greatest effect on SPAS. In the normal group, there was a
statistically significant difference between the SPAS scores
across the different isoluminant colors (P < 0.0001; 1-way
repeated measures ANOVA). The large red circle (LRC) SPAS (40
6 15) and large blue circle (LBC) SPAS (41 6 16) were both
significantly higher than the isoluminant (gray) large dim circle
(LDC) (16 6 9); but in normals, they were not significantly
different from each other (P < 0.05, Tukey’s multiple com-
parison test). In the ACHM group, again there was a statistically
significant difference between the SPAS scores across the
different isoluminant colors (P < 0.0001; 1-way repeated
measures ANOVA). However, unlike in the normal group, the
ACHM group displayed a significant difference in their SPAS
between the LRC and LBC stimuli, with the ACHM LRC SPAS (11
6 12) being significantly lower than the ACHM LBC SPAS (37 6
18; P < 0.05, Tukey’s multiple comparison test; Fig. 5).
Again, taking the bright central (circle) stimuli for
comparison, there were significantly higher SPAS for the larger
stimuli compared to the smaller stimuli in both the normal
(LWC SPAS¼ 62 6 17 and small white circle (SWC) SPAS¼ 46
6 17; P < 0.0001; paired t-test) and ACHM groups (LWC SPAS
¼ 62 6 20 and SWC SPAS¼ 47 6 16; P < 0.0001; paired t-test).
There was little effect from the location of the stimuli
(central versus peripheral). In the normal group the central
FIGURE 3. A pie chart showing the relative proportions of 26 ACHM patients that would choose to remedy one of the listed symptoms of ACHM
above all others. It can be seen that a significant proportion (38%) would rate PA as the one aspect of their condition that they would most like to
improve.
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(LWC) SPAS¼ 62 6 17 and the peripheral (large white annulus
[LWA]) SPAS ¼ 58 6 17, and in the ACHM group, the central
(LWC) SPAS¼ 61 6 20 and the peripheral (LWA) SPAS¼ 57 6
19; with the difference between location in each group being
statistically insignificant (P > 0.05; paired t-test).
Visual Acuity Measurements in Different Ambient
Lighting Conditions
Mean logMAR BCVA measurements were as follows in the two
ambient lighting conditions tested: brighter ambient lighting
conditions (250 cd/m2): OD 0.89 logMAR (95% confidence
interval [CI] 0.84–0.95); OS 0.95 logMAR (95% CI 0.88–1.0);
and OU 0.88 logMAR (95% CI 0.83–0.94); dimmer ambient
lighting conditions (155 cd/m2): OD 0.89 logMAR (95% CI
0.84–0.95); OS 0.92 logMAR (95% CI 0.87–0.97); and OU 0.84
logMAR (95% CI 0.79–0.90).
There was no statistically significant difference between
measured uniocular BCVA in the brighter and dimmer ambient
lighting conditions in the right eye (P ¼ 0.98; paired t-test) or
the left eye (P ¼ 0.69; paired t-test). However, there was a
statistically significant difference between the mean BCVAs
between conditions when measured binocularly (P ¼ 0.007,
paired t-test).
Results of Palpebral Aperture Measurements
A subset of 13 ACHM patients were tested with the lower light
intensity used by Zelinger et al.22 (0.6 cd/m2) and of these, 10
also undertook the experiment with the brighter intensity
(16.6 cd/m2). We tested 10 normal subjects at both light
intensities for comparison to the ACHM group.
The 13 ACHM patients who underwent palpebral aperture
measurements (seven males [54%] and six females [46%]) had a
mean age of 33 years (SD 6 12.01). Their genotype breakdown
was six CNGB3 (46%); three CNGA3 (23%); two ATF6 (15%);
one GNAT2 (8%); and one PDE6C (8%). The normals consisted
of four males (40%) and six females (60%), with a mean age of
37 years (SD 6 11.82).
The mean percentage of dark-state palpebral aperture after
a transition to a light of 0.6 cd/m2 was 94% (SD 6 8%) in the
FIGURE 4. Photoaversion subjective quantification task results. The four graphs show the subjective PA scores of 26 ACHM and 26 normal subjects,
scored out of 100 (see ‘‘Methods’’ section for definition). Each patient’s score for each stimulus was the average of three runs. Shown are the mean
(symbols) and SD (vertical bars) of each stimulus score (see stimuli descriptors below) for normals and ACHM subjects as indicated on the abscissa.
Graph symbols are in the color and form of the stimulus they represent in order to aid ease of interpretation. Stimuli descriptors: L, large; S, small; W,
white; D, dim (gray); R, red; G, green; B, blue; C, circle (central); A, annulus (peripheral; e.g., SDA, small dim annulus). * Indicates statistically
significant difference between groups at P < 0.0001; paired t-test.
TABLE. Mean SPAS for ACHM and Normal Subjects Viewing Bright
White Versus Dim Gray Stimuli (SD)
Normal Subjects
LWC 62 (617) LDC 16 (69) P < 0.0001*
SWC 46 (617) SDC 14 (66) P < 0.0001*
LWA 58 (617) LDA 19 (69) P < 0.0001*
SWA 41 (6157) SDA 16 (68) P < 0.0001*
ACHM Subjects
LWC 62 (620) LDC 18 (614) P < 0.0001*
SWC 47 (616) SDC 15 (613) P < 0.0001*
LWA 58 (619) LDA 17 (613) P < 0.0001*
SWA 43 (618) SDA 14 (611) P < 0.0001*
LDA, large dim annulus; SWA, small white annulus.
* P values are as calculated by the paired t-test. Mean SPAS scores
were significantly higher for bright stimuli in all comparable conditions
(i.e., size [large or small] or location [central circle or peripheral
annulus]) in both ACHM and normal subjects.
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ACHM group versus 98% (SD 6 6%) in the normal group. With
the experiment repeated but with a transition to a brighter
16.6 cd/m2, the mean percentage of dark-state palpebral
aperture was 56% (SD 6 8%) in the ACHM group versus 92%
(SD 6 10%) in the normal group (Fig. 6).
There was no statistically significant difference between the
palpebral aperture narrowing in the ACHM versus normal
group using the 0.6 cd/m2 intensity light (P¼ 0.21; unpaired t-
test), but with the 16.6 cd/m2 intensity light the ACHM group
had significantly more palpebral aperture narrowing that the
normal group (P < 0.0001; unpaired t-test). These findings are
reproducible when ACHM subjects are tested in monocular
viewing conditions, and would be likely assessed in an
interventional trial with treatment of one eye only (Fig. 6).
Palpebral narrowing is not significantly different between
binocular, monocular OD, and OS viewing conditions in the
ACHM group (P ¼ 0.91; Friedman test for the matched data
points; and for the unmatched data points binocular versus OD
eye P¼ 0.75, binocular vs. OS eye P¼ 0.86; Mann-Whitney U
test).
DISCUSSION
Structured Patient Survey
That 92% of patients in this study stated that bright lights
caused them more problems with difficulty seeing, as opposed
to discomfort/pain, indicates that the widely stated notion in
the literature that ACHM patients suffer discomfort/photopho-
bia with bright light may not represent the full picture of PA in
ACHM. It may well be that visual image degradation with bright
lights is also a significant issue for patients with ACHM. The
observations of Aguilar et al.32 that ACHM subjects had
significantly (P < 0.0001) lower discomfort thresholds
compared to normal subjects is interesting when viewed in
the light of our results, where 92% of patients reported that
reduced VA affects them more than discomfort. One might
therefore infer from the combined results of this work and
Aguilar et al.,32 that both PA induced discomfort and
hemeralopia are significant factors for patients in ACHM-
associated PA. Two comments from the final question (Is there
FIGURE 5. The color effect on SPAS in normals versus ACHM. All stimuli (large central circles) are isoluminant and their color is indicated by their
stimuli indicator code (see text) on the abscissa and the data symbols’ color. It can be seen that in the normal group, the blue and red stimuli score
significantly higher SPAS than the dim (gray) stimuli despite being isoluminant; but in the ACHM group, only the blue stimuli score significantly
higher SPAS than the dim (gray) stimuli. * Indicates statistically significant difference between groups at P < 0.05; Tukey’s multiple comparison test.
FIGURE 6. Plots of the relative palpebral aperture percentage after a transition from a dark state to one of two Ganzfeld stimulator lighting
intensities (0.6 cd/m2 and 16.6 cd/m2 as indicated) in ACHM subjects (red circles) versus normal subjects (green triangles). Horizontal plot lines
indicate the mean and whiskers indicate the SD of the values plotted. There is minimal difference in palpebral aperture narrowing between the
ACHM and normal groups with the onset of a 0.6 cd/m2 light from a dark state (binocular viewing; left plot); but with the onset of a 16.6 cd/m2 light,
the ACHM group has significantly more palpebral aperture narrowing than the normal group (binocular viewing; right plot). These findings are
reproducible when ACHM subjects are tested in monocular right (OD) or left (OS) eye viewing conditions (right plot). * Indicates statistically
significant difference between groups at P < 0.0001; 1-way ANOVA with Dunnett’s multiple comparisons test.
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anything else you would like to add about light sensitivity that
we have not covered?) appear to sum up, in the patients’ own
words, this message:
‘‘It can be embarrassing having to wear sunglasses in even
moderately bright places. It can be depressing at times also’’
and ‘‘basically all of my life is affected by light sensitivity in
some form.’’
Our survey shows that PA is a major symptom in ACHM
patients’ lives, with 20% of patients experiencing marked
limitation in their ability to carry out ADLs, and 38% saying that
it is the one symptom that they would want to have remedied
above all others (including VA [54%] or color vision [8%]).
These data also demonstrate that measures such as sunglasses
and tinted contact lenses may not fully alleviate all detrimental
aspects of PA as experienced by patients. However, it must be
kept in mind that given this was a survey about PA, this may
have primed the subjects and introduced bias to their
weighting of such a symptom.36 Treatment of animal models
has thus far been directed to restore cone function and visually
directed behavior, but no assessment of PA has been
undertaken.
We demonstrate that PA may also entail a socioeconomic
burden, affecting ability to work (94%) and perceived
employment prospects (73%), which suggest that there would
also be socioeconomic benefits for ACHM patients in
alleviating this symptom.
Quantitative Subjective Measurement of PA Task
That red and blue stimuli cause more photoaversion in normals
than isoluminant gray stimuli had been previously report-
ed,24,25 and demonstrates that this testing paradigm is sensitive
enough to corroborate previous observations. That the ACHM
group has significantly lower SPAS for the red stimuli compared
to either the blue or the dim (gray) stimuli is physiologically
expected, given that the spectral sensitivity of the achromats’
functioning rod photoreceptors (498 nm) is furthest away from
the red stimuli. Whether the significantly higher SPAS scores
for blue stimuli is due to rod input, a lack of cone input, ipRGC
input, or a combination of these factors remains to be
elucidated. The finding that larger stimuli also induced higher
SPAS scores is also previously reported30 and again a
physiologically plausible effect. An interesting application of
this paradigm would be to repeat the test in an ACHM group
pre- and postintervention, and examine whether SPAS scores
for red stimuli increased, to then mirror the normals’
equivalence with blue stimuli. This would possibly indicate
that there had been therapeutically induced LW-cone input to
the PA sensation pathways.
The absolute SPAS ratings between ACHM and normals
were very similar across all like-for-like comparisons. This
might be explainable by the fact that this was a relative rating
task, and so one might expect the psychometric scores to be
similar given that on one hand ACHM patients are more
photoaverse than normals (perhaps leading to higher SPAS
scores than normals), but they also experience more PA in
their daily lives, so the relatively low intensities used on the
display monitor may induce relatively minor PA compared to
the more severe PA that they normally endure (perhaps leading
to lower SPAS scores than normals).
That there was little effect from the location of the stimuli
(central versus peripheral) may be due to the fact that the
peripheral stimuli were still relatively central. Stringham et al.30
demonstrated that although PA thresholds increased (and
therefore PA light sensitivity decreased) with retinal eccentric-
ity, they did not increase significantly until at 208 eccentricity,
whereas the large perimeter of the annulus stimuli used in this
experiment only extended about 148 either side of fixation due
to constraints in designing the stimuli size so they were
consistent in area with the large central circle stimuli.
Visual Acuity Measurements in Different Ambient
Lighting Conditions
In the two conditions tested, we found no statistically
significant difference in uniocular BCVA between brighter or
dimmer ambient lighting. However, we did find a statistically
significant difference in binocular BCVA testing conditions.
One possible explanation might be that this is a statistical but
not clinically significant difference, given that the mean of the
improved difference in the dimmer versus brighter ambient
lighting condition in binocular assessments was small (0.04
logMAR, equivalent to only 2 letters on the ETDRS chart).
However, given the results of the structured survey (where
92% of patients indicated that PA troubles them most through a
reduction in detailed vision), it is likely that patients do
experience some form of degradation in VA in brighter lighting
conditions. It may be that the ‘‘bright’’ lighting conditions used
herein were not bright enough; the illuminance of the ‘‘bright’’
ambient light setting was 400 lux (which might equate to the
illuminance in an office or at sunrise/sunset) whereas
illuminances might be considerably higher outdoors in other
circumstances (e.g., 1000 lux on an overcast day or 10,000 lux
in full daylight).
One other intriguing possible explanation for the difference
in BCVA findings in uniocular versus binocular measurements
may be related to summation of photophobia inputs between
eyes. Wirtschafter et al.35 demonstrated that the photophobia
threshold in migraineurs is lowered (and therefore PA light
sensitivity is increased) in binocular versus uniocular viewing.
Therefore, an alternative explanation could be the larger effect
of PA when viewed with both eyes. Further testing of patients
in wider ranges of lighting conditions would be required to
probe the extent of visual degradation and painful discomfort
in ACHM with varying ambient lighting conditions. The
consistency of ambient lighting conditions in recording ACHM
patients’ BCVA pre- and post-treatment should also be borne in
mind.
Palpebral Aperture Measurements
Employing a light intensity of 16.6 cd/m2 we observed a 56%
eyelid separation in ACHMs and minimal change (92%) in the
normal group. This contrasted with the results reported by
Zelinger et al.22 of 50% reduction in palpebral aperture in the
three ACHM subjects that they tested using a lower light
intensity of 0.6 cd/m2. The reason for this difference is not
clear. Our larger ACHM group included various genotypes,
whereas their group only included CNGA3 subjects. A post-hoc
subgroup analysis of our data revealed that the mean palpebral
aperture using 0.6 cd/m2 in the CNGA3 subgroup was 98% (SD
6 3%) versus 90% (SD 6 11%) in the other genotypes
combined; and using the 16.6 cd/m2 light, the CNGA3
subgroup was 58% (SD 6 12%) versus 56% (SD 6 7%) in the
other genotypes combined. It appears that the CNGA3
subgroup is not significantly more or less photoaverse than
other genotypes combined, although the relatively low number
of patients of each genotype tested precludes more statistical
cross-group comparisons. It would be of interest to carry out
these experiments in larger numbers of each genotype to
determine if there is any difference between genotypes.
Notwithstanding the above, this experiment suggests that
an intensity of 16.6 cd/m2 would be an appropriate luminance
setting to assess PA-induced palpebral aperture changes in
ACHM pre- and post-treatment, given the statistically significant
difference in palpebral aperture narrowing in ACHM patients
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using this luminance versus no significant palpebral aperture
narrowing in the normal group. Importantly, we have also
established that this light level produces similar results in the
monocular viewing condition when compared to the binocular
viewing condition; this is relevant as any therapeutic trial is
likely to treat only one eye.
In conclusion, this study demonstrates—with an evidence
base for the first time in the literature—that PA is a significant
symptom for ACHM patients. This may have implications for
the direction of development of future treatment strategies for
ACHM. The evidence from this study suggests that, given the
importance of this symptom to many ACHM patients, PA could
be considered as an additional outcome measure in therapeutic
trials. We have also shown for the first time that PA in ACHM is
due more to the perceived visual degradation of the patient’s
visual image, as opposed to a physical sensation of pain or
discomfort. This has implications for doctors’ understanding of
what ACHM patients actually experience, and suggests that the
classical term ‘‘photophobia,’’ which is used ubiquitously in
the ACHM literature, should be replaced with the term
‘‘photoaversion,’’ since the former is commonly held to mean
a noxious sensation induced by normal light levels.
We have developed a quantitative SPAS task that can be
used to assess ACHM patients’ PA without subjecting them to
the bright light intensities that have been used in traditional
threshold photophobia testing paradigms at use in other
conditions, and have developed a normative group dataset in
this task for comparison. We have further developed an
objective measure of PA in the existing palpebral aperture
testing method that reliably distinguishes normals from ACHM
in monocular viewing conditions most likely to be relevant to
future treatment interventions, and have shown that the light
intensities previously published in a very small number of
ACHM patients using a similar method are unlikely to be
intense enough, and have suggested a suitable light intensity.
This SPAS testing paradigm and the palpebral aperture settings,
in addition to the structured survey, may be useful in
monitoring the significant symptom of PA pre-and post-
interventional gene therapy trials, with hopeful improvement
of these parameters following treatment.
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